Table 2 Univariate analysis with regard to tumor progression or death
From: Effect of long-term adjuvant temozolomide chemotherapy on primary glioblastoma patient survival
Patient number | PFS | P值 | OS | P | |
|---|---|---|---|---|---|
HR(95%CI) | HR(95%CI) | ||||
Age | |||||
< 45 | 32 | 1 | 1 | ||
> 45 | 21 | 1.227 | 0.511 | 1.341 | 0.384 |
(0.667–2.258) | (0.692–2.597) | ||||
Sex | |||||
Female | 23 | 1 | 1 | ||
Male | 30 | 1.062 | 0.843 | 1.19 | 0.586 |
(0.587–1.920) | (0.629–2.269) | ||||
Pre-surgery KPS | |||||
< 80 | 11 | 1 | 1 | ||
> 80 | 42 | 0.701 | 0.33 | 0.387 | 0.013 |
(0.343–1.434) | (0.183–0.817) | ||||
Brain lobes involved in tumor | |||||
Single lobe | 34 | 1 | 1 | ||
Multiple lobes | 19 | 0.521 | 0.04 | 0.783 | 0.365 |
(0.278–0.975) | (0.382–1.424) | ||||
MGMT methylation | |||||
No | 23 | 1 | 1 | ||
Yes | 26 | 0.343 | < 0.001 | 0.379 | 0.005 |
(0.178–0.663) | (0.192–0.748) | ||||
IDH | |||||
Wild-Type | 29 | 1 | 1 | ||
Mutation | 10 | 0.222 | 0.01 | 0.112 | < 0.001 |
(0.682–0.07) | (0.027–0.56) | ||||
TMZ therapeutic cycles | |||||
6 | 27 | 1 | 1 | ||
> 6 | 26 | 0.454 | 0.01 | 0.628 | 0.159 |
(0.244–0.842) | (0.324–1.215) | ||||